SCYNEXIS/SCYX

$1.44

-9.68%
-
1D1W1MYTD1YMAX

About SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Ticker

SCYX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Angulo

Employees

29

Headquarters

Jersey city, United States

SCYNEXIS Metrics

BasicAdvanced
$59.65M
Market cap
1.22
P/E ratio
$1.29
EPS
1.55
Beta
-
Dividend rate
$59.65M
1.54509
$3.87
$1.35
191.41K
6.264
6.264
16.665
16.665
33.49%
62.01%
175.97%
73.55%
1.221
0.426
0.806
0.818
0.992
2,652.74%
192.14%

What the Analysts think about SCYNEXIS

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
447.22% upside
High $10.00
Low $6.00
$1.44
Current price
$7.88
Average price target

SCYNEXIS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-342.1% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$5.7M
235.29%
Net income
$-19.5M
1,047.06%
Profit margin
-342.1%
242.1%

SCYNEXIS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 95%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.71
$2.46
-$0.04
-$0.39
-
Expected
-$0.28
$1.55
-$0.15
-$0.20
-$0.19
Surprise
155.4%
58.91%
-72.6%
95%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for SCYNEXIS stock?

SCYNEXIS (SCYX) has a market cap of $59.65M as of April 13, 2024.

What is the P/E ratio for SCYNEXIS stock?

The price to earnings (P/E) ratio for SCYNEXIS (SCYX) stock is 1.22 as of April 13, 2024.

Does SCYNEXIS stock pay dividends?

No, SCYNEXIS (SCYX) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next SCYNEXIS dividend payment date?

SCYNEXIS (SCYX) stock does not pay dividends to its shareholders.

What is the beta indicator for SCYNEXIS?

SCYNEXIS (SCYX) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the SCYNEXIS stock price target?

The target price for SCYNEXIS (SCYX) stock is $7.88, which is 447.22% above the current price of $1.44. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell SCYNEXIS stock

Buy or sell SCYNEXIS stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing